Introduction
Human immunodeficiency virus (HIV) infection results in a progressive immunodeficiency primarily affecting T cell mediated immunity. It is also associated with direct damage to other organs including the brain and gastrointestinal tract which may be the direct result of either primary viral pathogenicity or a consequence of immunopathological effects. This review will cover only aspects of the clinical presentation of HIV-infection resulting from the associated immunodeficiency and its laboratory assessment.
Accurate clinical staging is essential for epidemiological monitoring of the HIV epidemic, overall, in patient selection for clinical trials, and is of increasing importance in the assessment of individual patients for therapeutic intervention. Laboratory monitoring is gaining increasing importance in the initial staging of disease in individual patients, in the identification of immunological progression of those patients who remain asymptomatic, and in the recruitment to Clinical presentation and natural history of disease is less predictable and more diverse in children who have acquired the infection vertically during gestation or at childbirth, and is beyond the scope of this article. Readers are referred to review articles dealing specifically with paediatric aspects of HIV infection. 5 7 Because viral infection in adults, and the associated immunodeficiency, is progressive in most individuals, several clinical staging systems have been proposed which are essentially hierarchical and describe events which once occurred do not revert to earlier stages. However, with the increasing use of specific treatment in patients it is now possible in practice to return patients temporarily to earlier levels of such classifications. Such reversion is seen particularly in laboratory markers of immunological progression in patients receiving antiretroviral treatment.
The most widely adopted Centers for Disease Control (CDC) clinical staging system of HIV infection is reproduced in table 1 but may soon be replaced by a proposed CDC/WHO classification which will incorporate both laboratory and clinical markers (table 2) . The proposed new classification recognises the importance of the long asymptomatic stage of disease in determining the eventual outcome of 
Following the first detection of HIV infection, the immune status of every individual should be assessed to guide clinical and therapeutic decision making. This is forcing reappraisal of the long asymptomatic phase of the disease and is the reason for the introduction of immunological subdivisions of this stage of disease.
Increasing experimental evidence suggests that the early stages of HIV infection are generally associated with a strong and partially effective anti-HIV immune response which is associated with the reduction of initially high levels of virus replication."3 This state of relative immunity can persist for many years but is apparently eroded by the ease with which HIV mutates away from effective specific antibody and cellular responses.14 However, the observations from natural history studies which suggest that immune responses can effectively suppress viral replication in the early stages of infection for many years gives hope that earlier therapeutic intervention may be associated with considerably enhanced survival.
Many immunological parameters are influ- 
